Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Liabilities and Shareholders Equity (2023 - 2026)

MBX Biosciences has reported Liabilities and Shareholders Equity over the past 4 years, most recently at $452.7 million for Q1 2026.

  • Quarterly results put Liabilities and Shareholders Equity at $452.7 million for Q1 2026, up 84.08% from a year ago — trailing twelve months through Mar 2026 was $1.5 billion (up 84.4% YoY), and the annual figure for FY2025 was $385.1 million, up 43.42%.
  • Liabilities and Shareholders Equity reached $452.7 million in Q1 2026 per MBX's latest filing, up from $385.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $452.7 million in Q1 2026 and bottomed at $84.2 million in Q4 2023.
  • Median Liabilities and Shareholders Equity over the past 4 years was $275.5 million (2024), compared with a mean of $293.8 million.
  • The largest annual shift saw Liabilities and Shareholders Equity surged 219.0% in 2024 before it skyrocketed 41.67% in 2025.
  • Over 4 years, Liabilities and Shareholders Equity stood at $84.2 million in 2023, then soared by 219.0% to $268.5 million in 2024, then skyrocketed by 43.42% to $385.1 million in 2025, then grew by 17.54% to $452.7 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for MBX at $452.7 million in Q1 2026, $385.1 million in Q4 2025, and $400.1 million in Q3 2025.